Humulin R (Insulin Human (Rdna))

Humulin R is a recombinant human insulin (Insulin human) supplied as a 100 U/mL injectable solution for subcutaneous administration. It is a short‑acting insulin indicated for the management of diabetes mellitus and is marketed in the European Union as a prescription‑only product.

Humulin R is used to control blood glucose levels in patients with diabetes. It is appropriate for both type 1 and type 2 diabetes and may be employed as part of a basal‑bolus regimen or in combination with other antidiabetic agents.

- Initiation of insulin therapy in newly diagnosed type 1 diabetes. - Supplemental insulin for type 2 diabetes when oral agents are insufficient. - Management of hyperglycemia during illness or stress. - Adjunctive therapy in diabetic ketoacidosis after initial fluid and electrolyte replacement. - Adjustments for meals and physical activity in insulin‑treated patients.

Humulin R may cause a range of adverse reactions, ranging from mild to severe. Awareness of common and serious events helps clinicians monitor patients effectively.

Common: - Hypoglycemia (low blood glucose) - Injection‑site pain or erythema - Lipodystrophy at the injection site - Weight gain - Allergic skin reactions such as rash or pruritus

Serious: - Severe hypoglycemia with neuroglycopenic symptoms - Anaphylactic reaction or angioedema - Persistent hyperglycemia indicating insulin resistance - Edema or congestive heart failure exacerbation - Hypersensitivity leading to urticaria or bronchospasm

When prescribing Humulin R, clinicians should consider patient‑specific factors and monitor for potential complications.

- Assess renal and hepatic function before initiating therapy. - Adjust dose in patients with fluctuating dietary intake or exercise patterns. - Use caution in pregnant or breastfeeding women; category B indicates no proven risk. - Monitor for signs of hypoglycemia, especially in the elderly or those with impaired awareness. - Educate patients on proper injection technique to reduce lipodystrophy. - Review concomitant medications that may mask hypoglycemia symptoms.

Humulin R can interact with several drug classes, influencing its efficacy or safety profile.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment, which may precipitate severe hypoglycemia. - Beta‑blockers that can blunt hypoglycemia warning signs.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which may raise glucose levels and require dose escalation. - Diuretics, especially thiazides, that can affect electrolyte balance and glucose control. - ACE inhibitors or ARBs, which may potentiate insulin’s glucose‑lowering effect. - Alcohol, as it can cause unpredictable glucose fluctuations.